Liver Update: Screening diabetic patients for NAFLD with controlled attenuation parameter and liver stiffness measurements |
News and Updates
eMediNexus Coverage from: 
Liver Update: Screening diabetic patients for NAFLD with controlled attenuation parameter and liver stiffness measurements

2 Read Comments                

Type 2 diabetes increases the risk for non-alcoholic fatty liver disease (NAFLD), but current guidelines do not clearly explain screening for NAFLD in diabetic patients. A study investigated the strategy of screening diabetic patients by FibroScan.Controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) were used for assessing Liver fat and fibrosis by FibroScan. Advanced fibrosis was identified by Probe-specific LSM cut-offs.The observations of the study were as follows-191...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now